Login to Your Account

Bayhill Therapeutics Snags $350M Deal with Genentech

By Donna Young

Thursday, June 11, 2009
Privately held Bayhill Therapeutics Inc. stands to gain more than $350 million, including $25 million up front in cash and equity, from biotech giant Genentech Inc. in exchange for the worldwide development and commercialization rights for BHT-3021, which is being investigated as an immunotherapy for Type I diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription